Article Type
News
Changed
Tue, 05/21/2019 - 12:22
Display Headline
Counseling our patients regarding cycle control

Unscheduled bleeding (ie, spotting/breakthrough bleeding) and early, late, or absent withdrawal bleeding are common reasons cited by women for discontinuing use of oral contraceptives (OCs).3-5 A European survey of nearly 7000 current or past users of OCs found that women who experienced side effects such as unscheduled bleeding in the first 3 months of use were nearly twice as likely to discontinue use as those who reported no cycle control problems during this time.4

Sponsor
Sponsored by and content developed in conjunction with Ortho Women's Health and…
Article PDF
supplOBG_OCs.pdf
Author and Disclosure Information

 

Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine–Jacksonville, Jacksonville, Florida

Catherine L. Dean, MD, MPH
Clinical Assistant Professor, Department of Obstetrics and Gynecology, Washington University School of Medicine, Managing Partner, Women’s HealthPartners, Inc., St. Louis, Missouri

Dr Kaunitz reports the following:
Consultant and/or speakers bureau, and research support: Bayer HealthCare Pharmaceuticals, Merck & Co., Inc., Ortho Women’s Health & Urology™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd. Dr Kaunitz has been compensated for his work on this publication.

Dr Dean reports the following:
Speakers bureau: Bayer HealthCare Pharmaceuticals, and Ortho Women’s Health & Urology™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Dr Dean has been compensated for her work on this publication.

Publications
MDedge ObGyn
OBG Management
Legacy Keywords
Counseling our patients regarding cycle control;Andrew M. Kaunitz;MD;Catherine L. Dean;MD;supplement;Ortho Womens Health & Urology;Ortho-McNeil-Janssen Pharmaceuticals;Inc;
Sections
Medical Education Library
Supplements
Author and Disclosure Information

 

Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine–Jacksonville, Jacksonville, Florida

Catherine L. Dean, MD, MPH
Clinical Assistant Professor, Department of Obstetrics and Gynecology, Washington University School of Medicine, Managing Partner, Women’s HealthPartners, Inc., St. Louis, Missouri

Dr Kaunitz reports the following:
Consultant and/or speakers bureau, and research support: Bayer HealthCare Pharmaceuticals, Merck & Co., Inc., Ortho Women’s Health & Urology™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd. Dr Kaunitz has been compensated for his work on this publication.

Dr Dean reports the following:
Speakers bureau: Bayer HealthCare Pharmaceuticals, and Ortho Women’s Health & Urology™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Dr Dean has been compensated for her work on this publication.

Author and Disclosure Information

 

Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine–Jacksonville, Jacksonville, Florida

Catherine L. Dean, MD, MPH
Clinical Assistant Professor, Department of Obstetrics and Gynecology, Washington University School of Medicine, Managing Partner, Women’s HealthPartners, Inc., St. Louis, Missouri

Dr Kaunitz reports the following:
Consultant and/or speakers bureau, and research support: Bayer HealthCare Pharmaceuticals, Merck & Co., Inc., Ortho Women’s Health & Urology™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd. Dr Kaunitz has been compensated for his work on this publication.

Dr Dean reports the following:
Speakers bureau: Bayer HealthCare Pharmaceuticals, and Ortho Women’s Health & Urology™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Dr Dean has been compensated for her work on this publication.

Article PDF
supplOBG_OCs.pdf
Article PDF
supplOBG_OCs.pdf
Sponsor
Sponsored by and content developed in conjunction with Ortho Women's Health and…
Sponsor
Sponsored by and content developed in conjunction with Ortho Women's Health and…

Unscheduled bleeding (ie, spotting/breakthrough bleeding) and early, late, or absent withdrawal bleeding are common reasons cited by women for discontinuing use of oral contraceptives (OCs).3-5 A European survey of nearly 7000 current or past users of OCs found that women who experienced side effects such as unscheduled bleeding in the first 3 months of use were nearly twice as likely to discontinue use as those who reported no cycle control problems during this time.4

Unscheduled bleeding (ie, spotting/breakthrough bleeding) and early, late, or absent withdrawal bleeding are common reasons cited by women for discontinuing use of oral contraceptives (OCs).3-5 A European survey of nearly 7000 current or past users of OCs found that women who experienced side effects such as unscheduled bleeding in the first 3 months of use were nearly twice as likely to discontinue use as those who reported no cycle control problems during this time.4

Publications
MDedge ObGyn
OBG Management
Publications
MDedge ObGyn
OBG Management
Article Type
News
Display Headline
Counseling our patients regarding cycle control
Display Headline
Counseling our patients regarding cycle control
Legacy Keywords
Counseling our patients regarding cycle control;Andrew M. Kaunitz;MD;Catherine L. Dean;MD;supplement;Ortho Womens Health & Urology;Ortho-McNeil-Janssen Pharmaceuticals;Inc;
Legacy Keywords
Counseling our patients regarding cycle control;Andrew M. Kaunitz;MD;Catherine L. Dean;MD;supplement;Ortho Womens Health & Urology;Ortho-McNeil-Janssen Pharmaceuticals;Inc;
Sections
Medical Education Library
Supplements
Disallow All Ads
Alternative CME
Use ProPublica
Teaser Media
Article PDF Media